Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Total raised: $130M
Founded date: 2020
Investors 4
| Date | Name | Website |
| - | Takeda Ven... | takeda.com |
| 08.11.2023 | ARCH Ventu... | archventur... |
| - | DC Investm... | dcinvestme... |
| - | Atlas Vent... | atlasventu... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 18.04.2022 | - | $130M | - | finsmes.co... |
Mentions in press and media 1
| Date | Title | Description | Source |
| 18.04.2022 | Be Biopharma Closes $130M Financing | Be Biopharma, a Cambridge, MA-based developer of Engineered B Cell Medicines (BeCM), closed a $130m ... | finsmes.co... |